Outcomes, side effects, quality of life, and choosing a treatment that works FOR YOU!

Three articles in this week’s Journal of the American Medical Association throw a little more light on issues related to quality of life after diagnosis and treatment for localized prostate cancer … but quite how much light it is difficult to tell. … READ MORE …

No need to endure 38 to 44 treatments with IMRT anymore

There have been several hypofractionation trials maturing in the last couple of years. With minor exceptions, they all tell the same story: external beam radiation therapy (EBRT) can be completed in less time without loss of efficacy or increase in toxicity. … READ MORE …

Vasectomy and risk for prostate cancer — yet again …

So now we have data from a prospective study (carried out as part of the European Prospective Investigation into Cancer and Nutrition) that was designed (in part) to explore whether there was any association between vasectomy and risk for prostate cancer. … READ MORE …

Clinical trial design, clinical advice to patients, and clinical decision-making: not the same thing at all

In a recent opinion piece in the Journal of Clinical Oncology, Dr. Anthony D’Amico (a prostate cancer specialist for whom we have great respect) has again aired his concerns about risk for progression to metastatic disease among men on active surveillance. … READ MORE …

Informing the media community about prostate cancer and its management

A new article on the HealthNewsReview web site addresses issues related to the diagnosis of prostate cancer and the management of low-risk forms of the disease using active surveillance. … READ MORE …

Patients with certain KLK-6 mutations at risk for aggressive forms of prostate cancer

A newly published article in the Journal of the National Cancer Institute has suggested that men carrying a particular genetic mutation in the kallikrein 6 gene (KLK-6) have an increased risk for aggressive, clinically significant prostate cancer. … READ MORE …

Brachy boost: the gold standard for progression-free survival of high-risk prostate cancer

Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …